









Markets
/
Stocks
/
nasdaq-dmac
/

DiaMedica Therapeutics Inc

DMAC

8.140USD

+0.600+7.96%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

350.61MMarket Cap

LossP/E TTM



DiaMedica Therapeutics Inc

8.140

+0.600+7.96%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of DiaMedica Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

DiaMedica Therapeutics Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 141 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.50.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

DiaMedica Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

141 / 392

Overall Ranking

286 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

DiaMedica Therapeutics Inc Highlights

StrengthsRisks

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -11.35, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 20.19M shares, decreasing 0.00% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 723.12K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 1.96.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

15.500

Target Price

+105.57%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of DiaMedica Therapeutics Inc is 5.46, ranking 360 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.46

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.46

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

DiaMedica Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of DiaMedica Therapeutics Inc is 6.22, ranking 311 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -11.35, which is -77.51% below the recent high of -2.55 and -15.36% above the recent low of -13.09.

Score

Industry at a Glance

Previous score

6.22

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 141/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of DiaMedica Therapeutics Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 13.00, with a high of 25.00 and a low of 11.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

15.500

Target Price

+105.57%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

DiaMedica Therapeutics Inc

DMAC

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of DiaMedica Therapeutics Inc is 7.46, ranking 71 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 9.04 and the support level at 7.21, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.90

Change

0.56

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.099

Sell

RSI(14)

49.271

Neutral

STOCH(KDJ)(9,3,3)

30.334

Neutral

ATR(14)

0.610

High Vlolatility

CCI(14)

-48.661

Neutral

Williams %R

46.995

Neutral

TRIX(12,20)

-0.076

Sell

StochRSI(14)

76.427

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

8.032

Buy

MA10

8.239

Sell

MA20

8.194

Sell

MA50

8.414

Sell

MA100

7.600

Buy

MA200

6.097

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of DiaMedica Therapeutics Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 25.98%, representing a quarter-over-quarter decrease of 1.55%. The largest institutional shareholder is Leon Cooperman, holding a total of 3.27M shares, representing 6.28% of shares outstanding, with 65.70% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

EQT Partners AB

8.38M

+51.70%

Trill AB,LLC.

7.76M

+14.78%

Jacinto (Richard II)

4.96M

Omega Advisors, Inc.

Star Investors

3.27M

+5.13%

B. Riley Asset Management, LLC

2.21M

BlackRock Institutional Trust Company, N.A.

1.52M

+43.03%

Millennium Management LLC

1.19M

Paragon JV Partners, LLC

875.00K

+34.62%

The Vanguard Group, Inc.

Star Investors

664.58K

-56.71%

Geode Capital Management, L.L.C.

711.82K

+12.96%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of DiaMedica Therapeutics Inc is 3.67, ranking 128 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.09. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.